Loading patent…
AssigneePotentia Pharmaceuticals, Inc.
InventorsCedric Francois, Pascal Deschatelets, Paul Olson
Estimating the term…
The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
A method of treating an eye disorder characterized by macular degeneration, choroidal neovascularization, retinal neovascularization, or any combination of these, comprising steps of:
3-5. (canceled)
The method of claim 4, wherein the PVCCP is SPICE.
The method of claim 4, wherein the PVCCP is VCP.
8-12. (canceled)
(canceled)
(canceled)
A method of inhibiting neovascularization in the eye of a subject suffering from or at risk of an eye disorder characterized by macular degeneration, choroidal neovascularization, retinal neovascularization, or any combination of these, comprising the step of:
36-38. (canceled)
The method of claim 38, wherein the PVCCP is SPICE.
The method of claim 38, wherein the PVCCP is VCP.
41-44. (canceled)
(canceled)
(canceled)
(canceled)
61-91. (canceled)
A composition comprising a gel-forming material and a biological macromolecule that inhibits CNV, RNV, or both.
93-143. (canceled)
Dependencies are inferred from the claim text.